Prostaglandins, particularly prostaglandin E2 (PGE2), are potent regulators of bone resorption and formation. The identification of four different receptor types for PGE2 has made it possible to examine the pathways for different PGE2 effects on bone. Since endogenous PGE2 plays a critical role in skeletal responses to fracture, inflammation, mechanical loading, and possibly hormone deficiency, a definition of the specific roles of prostaglandin receptors is essential to fully understand skeletal physiology and pathophysiology and may lead to new therapies for bone loss and fracture healing. Our studies will focus on the role of EP2 and EP4 receptors (EP2R and EP4R). Activation of either receptor increases cAMP, but there are different responses to specific EP2R and EP4R agonists. Our current hypotheses concerning the roles of EP2R and EP4R in bone are as follows: (1) EP4R expression in osteoblasts is necessary for maximal support of osteoclast formation and bone resorption in response to PGE2; (2) EP2R in osteoblasts facilitates these responses, but an additional effect of EP2R in hematopoietic cells, possibly T-cells, can further enhance osteoclast formation; (3) Both EP2R and EP4R can mediate PGE2 stimulation of bone formation. To test these hypotheses, we have developed three Specific Aims. The first Specific Aim will examine the individual effects of deletion of EP2R or EP4R using both in vitro and in vivo models. To obtain viable mice with EP4R deletion (-/-), the deletion will be targeted to cells of the osteoblast lineage using Cre-lox methodology and two collagen promoters, Col 3.6 and Col 2.3, which are activated at different stages of osteoblast differentiation. The second Specific Aim will examine double deletion of EP2R and targeted EP4R, which should abrogate the cAMP response to PGE2, as well as specific EP2R and EP4R agonists in osteoblastic cells. The bones from both single and double knockout mice will be studied in cell and organ culture, and in vivo bone turnover in response to specific perturbations will be examined. In the third aim, the specific cells of the hematopoietic lineage involved in the EP2R enhancement of osteoclast formation will be determined using wild-type spleen cells and immunoseparation of the cell types. In addition, signal transduction pathways for enhanced osteoclastogenesis will be examined.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR018063-32
Application #
7390642
Study Section
Skeletal Biology Structure and Regeneration Study Section (SBSR)
Program Officer
Sharrock, William J
Project Start
1975-03-01
Project End
2010-03-31
Budget Start
2008-04-01
Budget End
2010-03-31
Support Year
32
Fiscal Year
2008
Total Cost
$306,527
Indirect Cost
Name
University of Connecticut
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
022254226
City
Farmington
State
CT
Country
United States
Zip Code
06030
Xu, Manshan; Choudhary, Shilpa; Voznesensky, Olga et al. (2010) Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice. Bone 47:341-52
Blackwell, Katherine A; Raisz, Lawrence G; Pilbeam, Carol C (2010) Prostaglandins in bone: bad cop, good cop? Trends Endocrinol Metab 21:294-301
Blackwell, Katherine A; Hortschansky, Peter; Sanovic, Srdan et al. (2009) Bone morphogenetic protein 2 enhances PGE(2)-stimulated osteoclast formation in murine bone marrow cultures. Prostaglandins Other Lipid Mediat 90:76-80
Gao, Qi; Zhan, Peili; Alander, Cynthia B et al. (2009) Effects of global or targeted deletion of the EP4 receptor on the response of osteoblasts to prostaglandin in vitro and on bone histomorphometry in aged mice. Bone 45:98-103
Gao, Qi; Xu, Manshan; Alander, Cynthia B et al. (2009) Effects of prostaglandin E2 on bone in mice in vivo. Prostaglandins Other Lipid Mediat 89:20-5
Choudhary, Shilpa; Alander, Cynthia; Zhan, Peili et al. (2008) Effect of deletion of the prostaglandin EP2 receptor on the anabolic response to prostaglandin E2 and a selective EP2 receptor agonist. Prostaglandins Other Lipid Mediat 86:35-40
Kaneko, H; Mehrotra, M; Alander, C et al. (2007) Effects of prostaglandin E2 and lipopolysaccharide on osteoclastogenesis in RAW 264.7 cells. Prostaglandins Leukot Essent Fatty Acids 77:181-6
Choudhary, Shilpa; Halbout, Philippe; Alander, Cynthia et al. (2007) Strontium ranelate promotes osteoblastic differentiation and mineralization of murine bone marrow stromal cells: involvement of prostaglandins. J Bone Miner Res 22:1002-10
Alander, Cynthia B; Raisz, Lawrence G (2006) Effects of selective prostaglandins E2 receptor agonists on cultured calvarial murine osteoblastic cells. Prostaglandins Other Lipid Mediat 81:178-83
Xu, Manshan; Choudhary, Shilpa; Goltzman, David et al. (2005) Do cyclooxygenase-2 knockout mice have primary hyperparathyroidism? Endocrinology 146:1843-53

Showing the most recent 10 out of 49 publications